Safety and Immunogenicity ofEscherichia coliO157 O‐Specific Polysaccharide Conjugate Vaccine in 2–5‐Year‐Old Children | Zendy

Amina Ahmed | Zendy; LI Jian-pin | Zendy; Yossi Shiloach | Zendy; John B. Robbins | Zendy; Shousun C. Szu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity ofEscherichia coliO157 O‐Specific Polysaccharide Conjugate Vaccine in 2–5‐Year‐Old Children

Author(s) -

Amina Ahmed,

LI Jian-pin,

Yossi Shiloach,

John B. Robbins,

Shousun C. Szu

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/499821

Subject(s) - immunogenicity , medicine , conjugate vaccine , titer , microbiology and biotechnology , antibody , immunology , escherichia coli , immunoglobulin g , vaccination , adverse effect , biology , biochemistry , gene

Escherichia coli O157:H7 causes severe enteritis and hemolytic-uremic syndrome, mostly in young children and older adults. Similar to the case with Shigella, serum IgG against the O-specific polysaccharide of E. coli O157:H7 may confer immunity by lysing the inoculum in the intestine. A phase 1 trial in adults showed that a vaccine of E. coli O157:H7 O-specific polysaccharide conjugated to recombinant exotoxin A of Pseudomonas aeruginosa (O157-rEPA) was safe and immunogenic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research